Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies

Institute for Biomedical Research, University of Birmingham, Birmingham, United Kingdom.
Hepatology (Impact Factor: 11.19). 01/2007; 47(1):17-24. DOI: 10.1002/hep.21959
Source: PubMed

ABSTRACT Hepatitis C virus (HCV) infection of Huh-7.5 hepatoma cells results in focal areas of infection where transmission is potentiated by cell-cell contact. To define route(s) of transmission, HCV was allowed to infect hepatoma cells in the presence or absence of antibodies that neutralize cell-free virus infectivity. Neutralizing antibodies (nAbs) reduced cell-free virus infectivity by >95% and had minimal effect(s) on the frequency of infected cells in the culture. To assess whether cell-cell transfer of viral infectivity occurs, HCV-infected cells were cocultured with fluorescently labeled naïve cells in the presence or absence of nAbs. Enumeration by flow cytometry demonstrated cell-cell transfer of infectivity in the presence or absence of nAbs and immunoglobulins from HCV(+) patients. The host cell molecule CD81 and the tight junction protein Claudin 1 (CLDN1) are critical factors defining HCV entry. Soluble CD81 and anti-CD81 abrogated cell-free infection of Huh-7.5 and partially inhibited cell-cell transfer of infection. CD81-negative HepG2 hepatoma cells were resistant to cell-free virus infection but became infected after coculturing with JFH-infected cells in the presence of nAb, confirming that CD81-independent routes of cell-cell transmission exist. Further experiments with 293T and 293T-CLDN1 targets suggested that cell-cell transmission is dependent on CLDN1 expression. Conclusion: These data suggest that HCV can transmit in vitro by at least two routes, cell-free virus infection and direct transfer between cells, with the latter offering a novel route for evading nAbs.


Available from: Geert Leroux-Roels, Jun 12, 2015
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To replicate its genome, a virus needs to cross the plasma membrane of a host cell and get access to cytosolic and/or nuclear components. For an enveloped virus, this involves binding to the plasma membrane, followed by migration of the virion to a microdomain or an endosomal vesicle where fusion between the virion envelope and a host cell membrane occurs. Increasing evidences indicate that virus entry is a tightly regulated process. Although we are still far from understanding the details of hepatitis C virus (HCV) entry, recent data show that this virus enters into target cells in a slow and complex multistep process involving the presence of several entry factors. Initial attachment of the virion may involve glycosaminoglycans and the low-density lipoprotein receptor, and it is followed by the sequential interaction with the scavenger receptor class B type I, the tetraspanin CD81 and tight junction protein Claudin-1, -6 or -9. Furthermore, the identification of EWI-2wint as a new partner of CD81 which blocks E2-CD81 interaction provides additional evidence of the complexity of the HCV entry process. The current knowledge accumulated on HCV entry is summarized in this review.
    Cellular Microbiology 05/2008; 10(4):821-7. DOI:10.1111/j.1462-5822.2007.01107.x · 4.82 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Infections with HCV represent a major global health problem. End-stage liver disease caused by chronic HCV infection is the most common indication for liver transplantation. Limited efficacy and severity of side effects hamper the use of pegylated interferon combined with ribavirin in a liver transplant setting. Therefore, new therapeutic options should be made available. Viral entry, the first step of the viral life cycle, represents an interesting target for therapeutic intervention. Understanding the mechanisms of viral entry is necessary to define the viral and cellular factors involved. In this review, we summarize these factors, highlight their potential as therapeutic targets and review the current (pre)clinical development of molecules that interfere with HCV entry.
    Future Virology 06/2012; 7(6-6):547-561. DOI:10.2217/fvl.12.47 · 1.00 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hepatitis C virus (HCV) causes chronic infection in up to 50-80% of infected individuals. Hypervariable region 1 (HVR1) variability is frequently studied to gain an insight into the mechanisms of HCV adaptation during chronic infection, but the changes to and persistence of HCV subpopulations during intra-host evolution are poorly understood. In this study, we have used ultra-deep pyrosequencing (UDPS) to map viral heterogeneity of a single patient over 9.6 years of chronic HCV genotype 4a infection. Informed error correction of the raw UDPS data was performed using a temporally matched clonal data set. The resultant data set reported the detection of low frequency recombinants throughout the study period implying that recombination is an active mechanism through which HCV can explore novel sequence space. The data indicates that poly-virus infection of hepatocytes has occurred but that the fitness quotients of recombinant daughter virions are too low to compete against the parental genomes. The subpopulations of parental genomes contributing to the recombination events highlighted a dynamic virome where subpopulations of variants are in competition. In addition, we provide direct evidence that demonstrates the growth of subdominant populations to dominance in the absence of a detectable humoral response.
    Journal of Virology 09/2014; DOI:10.1128/JVI.01732-14 · 4.65 Impact Factor